Left Ventricular Assist Device-Related Ventricular Arrhythmias

Durable left ventricular assist devices (LVADs) have changed the outlook for selected patients with advanced heart failure, providing circulatory support while they await transplantation or as long-term destination therapy. Ventricular tachycardia (VT) and ventricular fibrillation (VF), however, remain important complications. An LVAD can preserve systemic perfusion during an arrhythmic episode, yet the underlying electrical instability may still cause right ventricular failure, syncope, device alarms, thrombotic complications, or death.

The relationship between mechanical support and ventricular rhythm is complex. Some patients have recurrent monomorphic VT that existed before implantation; others develop new arrhythmias after myocardial unloading. Changes in ventricular geometry, myocardial scar, suction events, electrolyte disturbance, infection, and antiarrhythmic drug exposure can all contribute. Management therefore requires coordination between heart failure, electrophysiology, intensive care, and device teams.

For clinicians in Australia, care is concentrated in specialist centres such as those in Sydney, Melbourne, Brisbane, Perth and Adelaide. Patients may travel long distances for implantation, ablation, or transplantation review, making remote monitoring, clear escalation plans, and local emergency education essential. Ambulance clinicians and regional hospitals also need familiarity with LVAD alarms and the fact that a palpable pulse may be absent even when perfusion is adequate.

The Journal of Arrhythmia provides a useful setting for following developments in ventricular arrhythmia mechanisms, catheter ablation, implantable devices, and pharmacological treatment. Evidence continues to evolve, and decisions should be individualised according to haemodynamics, transplant eligibility, device type, ventricular substrate, and the patient’s goals of care.

Why Ventricular Arrhythmias Develop

Advanced heart failure creates a pro-arrhythmic substrate before an LVAD is implanted. Ischaemic scar, dilated or hypertrophic myocardium, fibrosis, neurohormonal activation, and heterogeneous conduction can support re-entry circuits. A patient with recurrent VT before implantation may therefore remain vulnerable after unloading. In some cases, the frequency falls as wall stress improves; in others, the arrhythmia persists because scar architecture is unchanged.

Mechanical unloading introduces additional electrophysiological changes. Reduced left ventricular volume can alter fibre stretch, repolarisation, and conduction pathways. The interventricular septum may shift towards the left ventricle when right-sided filling is poor or pump speed is excessive. This can change ventricular geometry and increase susceptibility to ventricular ectopy or sustained VT.

A suction event is a particularly important device-related trigger. It may occur when the left ventricle is underfilled because of hypovolaemia, right ventricular failure, tamponade, excessive pump speed, or sudden changes in preload. Contact between the inflow cannula and ventricular wall can produce alarms, haemodynamic deterioration, and ventricular arrhythmia. The diagnosis requires correlation between symptoms, pump parameters, echocardiography, volume status, and rhythm recordings rather than an isolated alarm interpretation.

Recognising The Clinical Pattern

The presentation ranges from asymptomatic non-sustained VT to electrical storm with repeated shocks and circulatory collapse. Continuous-flow support can maintain blood flow during VT, so the patient may remain conscious while the rhythm is dangerously rapid. Conversely, severe right ventricular dysfunction may make even a short episode poorly tolerated. Symptoms such as dizziness, dyspnoea, chest discomfort, reduced exercise capacity, or repeated implantable cardioverter-defibrillator (ICD) therapies require urgent review.

Assessment begins with the airway, breathing, circulation, neurological state, and LVAD function. A Doppler-derived mean arterial pressure, capillary refill, mental state, urine output, lactate, and device flow trends are often more informative than a conventional pulse or automated cuff. The controller should be checked for low-flow, high-power, or suction alarms, while the driveline and power sources are inspected.

A 12-lead ECG, device interrogation, electrolyte profile, blood gas, full blood count, renal and liver function tests, troponin where appropriate, and echocardiography help identify reversible causes. Clinicians should look for infection, bleeding, hypoxia, acidosis, acute coronary syndrome, pump thrombosis, worsening right heart failure, and medication interactions. In Australia, an LVAD patient presenting to a rural emergency department may require early telephone or telehealth contact with the implanting centre before transfer, particularly when transport time is substantial.

Acute Treatment And Stabilisation

Sustained VT with haemodynamic compromise requires immediate electrical cardioversion or defibrillation according to standard resuscitation principles. An LVAD does not remove the need to treat VF or unstable VT promptly. Defibrillation pads should be positioned to avoid the pump components and driveline where possible, while following local device-team guidance. In a cardiac arrest, resuscitation decisions should consider the cause, duration, neurological status, transplant pathway, and previously documented goals of care.

For stable monomorphic VT, intravenous amiodarone, lidocaine, or procainamide may be considered according to the clinical context and local protocols. Drug selection should account for renal function, hepatic function, QT interval, bradycardia risk, interactions with anticoagulants, and the patient’s transplant status. Repeated ICD shocks can increase sympathetic activation and perpetuate arrhythmia, so analgesia, sedation, and sympathetic suppression are important when clinically safe.

Correcting triggers is as important as suppressing the rhythm. Potassium and magnesium should be restored to appropriate targets, hypovolaemia should be treated cautiously, and excessive pump speed should be reviewed. A patient with suspected suction physiology may need volume assessment, speed adjustment, and urgent echocardiography. Inotropic support for right ventricular failure can be necessary, although catecholamines may worsen ventricular irritability and should be used with close monitoring.

Electrical storm calls for a coordinated strategy. Deep sedation, beta-adrenergic blockade, amiodarone, and urgent electrophysiology involvement may be required. Mechanical circulatory support can provide a bridge during refractory shock, but the chosen strategy depends on the existing LVAD, right ventricular performance, end-organ function, and access to an advanced heart failure service.

Catheter Ablation And Device Programming

Catheter ablation is an important option for recurrent VT, frequent ICD therapies, or electrical storm that persists after reversible factors and medical treatment have been addressed. The arrhythmogenic substrate may involve the ventricular septum, perivalvular regions, apical scar, or the inflow cannula area. Pre-procedure imaging and review of prior operative details can help define the likely circuits.

An endocardial approach is often used, but epicardial access may be needed for selected scar patterns. The LVAD inflow cannula creates procedural and imaging considerations, including the risk of catheter interaction with the device. Anticoagulation management must balance thromboembolism and bleeding, and the procedural plan should be agreed by electrophysiology, anaesthesia, cardiac surgery, and the LVAD team.

Ablation does not guarantee elimination of all ventricular arrhythmia. Scar progression, recurrent heart failure, infection, and changing loading conditions may create new circuits. Even so, reducing VT burden can limit ICD shocks, improve quality of life, and protect right ventricular function. Ablation before implantation may be considered in selected patients with a high arrhythmia burden, while post-implant ablation is often reserved for recurrence or refractory episodes.

ICD programming should be reviewed rather than simply increasing therapy intensity. Longer detection intervals, appropriate anti-tachycardia pacing, and carefully selected shock zones may reduce unnecessary shocks without compromising safety. A device clinic can also identify lead problems, sensing errors, and arrhythmia patterns. Remote monitoring is particularly valuable for Australians living far from tertiary centres, although it must be paired with a clear response pathway and reliable connectivity.

Long-Term Care And Australian Practice

Long-term management combines LVAD surveillance, rhythm follow-up, anticoagulation, heart failure treatment, infection prevention, and rehabilitation. Guideline-directed therapy may be limited by blood pressure, renal dysfunction, right ventricular failure, or drug interactions. Beta-blockers can reduce adrenergic drive, while amiodarone may be useful for recurrent VT but carries thyroid, pulmonary, hepatic, ocular, and neurological toxicity. Regular review is essential, especially when therapy continues for months.

The Australian market and regulatory environment shape access to care. LVAD systems and associated components must be supplied through appropriate Therapeutic Goods Administration pathways, while procurement, training, and servicing are generally organised through specialised hospital programs. The HeartMate 3 has become a prominent durable support option internationally, whereas the Medtronic HVAD system is no longer manufactured for new implants after its global withdrawal. Device-specific instructions remain essential because alarm meanings, controller functions, and replacement procedures differ.

Anticoagulation and antiplatelet treatment require close supervision. Bleeding, stroke, pump thrombosis, and gastrointestinal angiodysplasia can complicate attempts to prevent device thrombosis. Decisions should follow the device program’s protocol and account for procedures, falls, renal impairment, and interacting medicines. Australia’s state and territory health systems also mean that referral arrangements, retrieval pathways, and access to specialist follow-up may differ between New South Wales, Victoria, Queensland, Western Australia, South Australia, and other jurisdictions.

Patient education should reflect everyday life. People may need advice about showering, swimming, heat exposure, battery charging, travel, driving, and keeping spare equipment available. A patient attending a weekend gathering in Melbourne or travelling between Perth and regional Western Australia needs a written emergency plan, implanting-centre contact details, and information for local ambulance services. The device identification card should be carried at all times, and family members should know how to respond to alarms without disconnecting power sources unnecessarily.

Research priorities include better prediction of post-implant VT, integration of pump data with implantable device electrograms, improved mapping around cannula-related circuits, and strategies that protect the right ventricle. Clinicians can follow emerging evidence through the journal’s themed collections, which bring together research and reviews relevant to electrophysiology, ablation, pacing, and mechanical circulatory support.

Care teams should establish an arrhythmia plan before discharge, document emergency contacts, review ICD and pump settings regularly, and rehearse escalation procedures with patients and carers. Early specialist input, rapid correction of reversible triggers, and thoughtful integration of ablation, medication, device programming, and advanced heart failure care can reduce the burden of ventricular arrhythmias and support safer long-term LVAD therapy.